To conclude, our results are encouraging with respect to developing inhibitors of SIRT2, which are safe in terms of susceptibility to infections, for treating metabolic and neurodegenerative diseases, such as Parkinson’s disease and Huntington’s disease (90, 91). The gene discussed is SIRT2; the disease is juvenile Huntington disease.